Guangzhou Hanfang Pharmaceutical Co Ltd (Guangzhou Hanfang) has been granted a Certificate of Suitability to Monograph of European Pharmacopoeia (CEP) by the Certification Secretariat of the European Directorate for the Quality of Medicines & HealthCare (EDQM) for its anti-cancer product, vinorelbine tartrate.

The authorization means the European market has given a green light to the Guangzhou-based company and will help it enter the European market and step up the traditional Chinese medicine going global, said the company.

Guangzhou Hanfang is a subsidiary of Guangzhou Pharmaceutical Holding Ltd and mainly engages in the development and production of natural plant extracts, botanical and chemical drugs, intermediates and preparations, and natural health care products.

It is the Guangdong-only national engineering research and industrial demonstration center for modernization of extraction and separation of TCM.

Guangzhou Hanfang, set up in 2001, is the Guangdong-only national engineering research and industrial demonstration center for the modernization of extraction and separation of traditional Chinese medicine. [Photo/gpc.com.cn]

According to the company, Ganoderma Lucidum Spore Oil Soft Capsule, which is used to help to establish a strong immune system, is representative of the approved technology.

The CEP confirms that pharmaceutical substances or active pharmaceutical ingredients are produced according to the standards of the European Pharmacopoeia, known as one of the strictest standards for accreditation in the world.

Guangzhou Hanfang Pharmaceutical Co Ltd is granted a Certificate of Suitability to Monograph of European Pharmacopoeia (CEP) by the Certification Secretariat of the European Directorate for the Quality of Medicines & HealthCare. [Photo/gpc.com.cn]